The progress of postapproval clinical studies on Sabin IPV

Figures & data

Table 1. The sIPV immunogenicity evaluation in postmarket studies of the sIPV primary schedule and sIPV–bOPV sequential schedule in China

Vaccination schedule	sIPV antigen	Individuals Numbers	Location	Type 1		Type 2		Type 3		Ref.
				Seroconversion rate % (95%CI)	GMTs(95%CI)	Seroconversion rate % (95%CI)	GMTs(95%CI)	Seroconversion rate %(95%CI)	GMTs(95%CI)
sIPV-bOPV-bOPV sIPV-sIPV-bOPV	Type I: 30 DU Type II: 32 DU Type III: 45 DU	358	Chongqing	99.7	2896 (2586–3244)	74.58	19(15–25)	100	1079 (972–1199)	^Citation7
	Type I: 30 DU Type II: 32 DU Type III: 45 DU	158	Zhejiang	100	2048 (2048–2048)	62	12 (4–32)	100	2048 (1024–2048)	^Citation4
	Type I: 30 DU Type II: 32 DU Type III: 45 DU	170	Guangxi	99.4 (96.8–100.0)	5,303.9 (4610.5–6101.5)	51.8 (44.0–59.5)	11.7 (9.8–14.0)	99.4 (96.8–100.0)	1285.7 (1124.2–1470.4)	^Citation5
	Type I: 15 DU Type II: 45 DU Type III: 45 DU	69	Hebei	100	4907.8	97.6	41.6	100	1692.15	^Citation13
	Type I: 15 DU Type II: 45 DU Type III: 45 DU	189	Inner Mongolia, Shanxi, and Hebei	100 (98.07–100)	5029.8 (4435.2–5704.2)	91.53 (86.62–95.08)	38.1 (32.1–45.2)	100 (98.07–100)	1406.7 (1235.6–1601.5)	^Citation6
	Type I: 30 DU Type II: 32 DU Type III: 45 DU	70	Shanghai	100	840.9 (1715.6–1966.3)			100	1858.5 (1742.6–1973.5)	^Citation10
	Type I: 30 DU Type II: 32 DU Type III: 45 DU	152	Zhejiang	100	2048 (2048–2048)	95	64 (32–224)	100	2048 (2048–2048)	^Citation4
	Type I: 30 DU Type II: 32 DU Type III: 45 DU	180	Guangxi	98.9 (90.0–99.9)	7,359.6 (6379.2–8490.6)	79.4 (72.8–85.1)	73.4 (60.1–89.7)	99.4 (96.9–100.0)	2,941.1 (2493.7–3468.9)	^Citation5
	Type I: 30 DU Type II: 32 DU Type III: 45 DU	68	Hebai	100	7175.3	100	200.4	100	2986.3	^Citation13
	Type I: 15 DU Type II: 45 DU Type III: 45 DU	185	Inner Mongolia, Shanxi, and Hebei		9310.9 (8132.9–10659.5)	98.4 (95.3–99.7)	270.4 (230.1–317.8)	100 (98.03–100)	4065.4 (3483.7–4744.3)	^Citation6
sIPV-sIPV-sIPV	Type I: 30 DU Type II: 32 DU Type III: 45 DU	72	Shanghai	100	1085.6 (903.9–1267.2)			98.61	644.9 (518.7–771.1)	^Citation10
	Type I: 30 DU Type II: 32 DU Type III: 45 DU	163	Zhejiang	100	2048 (2048–2048)	99	256 (128–512)	100	512 (256–1024)	^Citation4
	Type I: 30 DU Type II: 32 DU Type III: 45 DU	1200	Yunnan	99.83 (98.1–100)	3283.3 (3091.7, 3488.9)	98.93 (96.9–99.6)	231.1 (217.3, 245.9)	99.9 (98.5–100)	932.0 (880.6, 986.3.0)	^Citation18
	Type I: 15 DU Type II: 45 DU Type III: 45 DU	195	Inner Mongolia, Shanxi, and Hebei	100 (98.1–100)	4476.7 (3982.0–5032.7)	99.5 (97.2–100)	510.2 (438.4–593.7)	100 (98.1–100)	1091.7 (942.2–1264.8)	^Citation6

sIPV: inactivated poliomyelitis vaccine made from Sabin strains; bOPV: bivalent oral poliomyelitis vaccine

Wang Q, Zhang Y, Xu J. [Immunogenicity of sequential polio vaccination schedules that use inactivated polio vaccine as the first dose]. Chin J Vacc Immun. 2019;25(4):378–82.

 Google Scholar

He H, Wang Y, Deng X, Yue C, Tang X, Li Y, Liu Y, Yin Z, Zhang G, Chen Z, et al. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial. Lancet Infect Dis. 2020;20(9):1071–79. doi:10.1016/S1473-3099(19)30738-8.

 PubMed Web of Science ®Google Scholar

Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, Yang X, Sun M, Jiang L, Shi L, et al. Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann Transl Med. 2021;9(3):253. doi:10.21037/atm-20-2537.

 PubMed Web of Science ®Google Scholar

Zhang J, Zhu Y, Xu X, Liu S, Wang J, Cong Y, et al. [Immunogenicity of two sequential primary immunization schedules with inactivated poliovirus vaccine and bivalent oral poliomyelitis attenuated live vaccine]. Chin J Biol. 2020;26(3):265–68.

 Google Scholar

Yan S, Chen H, Zhang Z, Chang S, Xiao Y, Luo L, Zhang Z, Sun L, Chen X, Yang Y, et al. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: a randomized, controlled, open-label, phase IV clinical trial in China. Vaccine. 2020;38(40):6274–79. doi:10.1016/j.vaccine.2020.07.042.

 PubMed Web of Science ®Google Scholar

Xiao S, Yang T, Fei Y, Deng P, Yang L. [Basic immune effect of sequential immunization with oral live attenuated vaccine and inactivated poliomyelitis vaccine]. Chin J Biol. 2020;33(07):809–12.

 Google Scholar

Hotta C, Ogawa T, Shirasawa H. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine. Hum Vaccin Immunother. 2019;15:1154–59. doi:10.1080/21645515.2019.1572408.

 PubMed Web of Science ®Google Scholar